50
Participants
Start Date
October 31, 2007
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
Sunitinib
The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
Memorial Sloan-Kettering Cancer Center, New York
Memorial Sloan-Kettering Cancer Center at Commack, Commack
University of Virginia Health Science Center, Charlottesville
Dana Farber Cancer Institute, Boston
Memoral Sloan Kettering Cancer Center, Basking Ridge
University of Pittsburgh Medical Center, Pittsburgh
Collaborators (1)
Dana-Farber Cancer Institute
OTHER
University of Virginia
OTHER
University of Pittsburgh
OTHER
Pfizer
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER